AMO Pharma Limited, a clinical-stage biopharmaceutical company focused on rare genetic disorders, announced on July 6, 2026, that it has reached agreement with regulatory agencies in the United States, United Kingdom, and Canada on the design for a registrational clinical study of its investigational therapy AMO-02 (oral tideglusib) for congenital myotonic dystrophy type 1 (cDM1). The study will evaluate hospitalization as the primary efficacy endpoint, supported by multiple functional assessments as secondary outcome measures.
Regulatory Alignment and Study Design
The design requirements and primary outcome choice are based on advice provided by the U.S. Food and Drug Administration (FDA), the U.K. Medicines and Healthcare products Regulatory Agency (MHRA), and Health Canada following meetings over the past six months. AMO-02 is an investigational compound that has not been approved by any regulatory authority, and its safety and efficacy have not yet been established.
Hospitalization was selected as the primary endpoint because it represents a significant burden for people living with cDM1 and their caregivers. cDM1 is a potentially life-threatening disorder associated with multiple medical co-morbidities that often require hospital care. The company also plans to engage the cDM1 community through a survey to better understand the impact of symptoms and hospitalizations associated with the disorder.
Secondary Outcome Measures and Disease Characterization
The clinical study will include a range of functional assessments as secondary outcome measures to help characterize disease progression and capture key features of cDM1, which can vary widely in its clinical presentation. According to Dr. Mike Snape, chief executive officer at AMO Pharma, “We appreciate the thoughtful engagement of FDA, MHRA and Health Canada throughout this important process and are pleased to have received feedback that informs the design of the planned registrational study for AMO-02. With insights from these regulatory agencies, we are now well positioned to plan and execute a registrational study as quickly as possible. For individuals and families affected by cDM1, the need for new treatment options remains critical, and we look forward to updating on our progress in advancing this program in the months ahead.”
Burden of Congenital Myotonic Dystrophy Type 1
Congenital DM1 is a rare, inherited neuromuscular disorder that can cause serious and lifelong challenges affecting muscle function, learning difficulties, development, cardiac problems, and overall health. Many affected individuals experience serious complications requiring hospitalization and ongoing multidisciplinary care. There are currently limited treatment options available for individuals living with the condition.
Lisa Harvey-Duren, a leading patient advocate in DM1 and a consultant for AMO Pharma, commented, “Families affected by cDM1 carry an extraordinary burden, often managing serious health challenges from the earliest days of life. Alignment on a trial design that reflects clinically meaningful outcomes is an important methodological step in evaluating potential therapies for cDM1. The selection of patient-relevant outcome measures is an important consideration in clinical research design for congenital myotonic dystrophy.”
